While the latest GLP-1 pricing headlines offer hope for individuals looking to access these medications at a lower cost, they raise concerns for employers and payers who must navigate utilization, coverage gaps, and budget implications
[79] Trials for cardiovascular health [edit] In March 2024, the US Food and Drug Administration expanded the indication for semaglutide (brand name Wegovy) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and who are either obese or overweight
Steatosis and fibrosis were assessed by vibration controlled transient elastography (VCTE) in terms of controlled-attenuation parameter (CAP) and liver stiffness measurement (LSM)
After completing a short online questionnaire about your health history, if qualified, youll start an on-demand video visit with a Walgreens Weight Management provider
Who Seems More Likely to Feel This Shift